ArticleBMC nephrology2026
Epidemiology, antimicrobial resistance, and mortality of bloodstream infections in hemodialysis patients: an 11-year retrospective cohort study from southern Saudi Arabia.
Article in BMC nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors.
Funding
Abstract
backgroundBloodstream infections (BSI) cause major morbidity and mortality in hemodialysis patients, yet contemporary Saudi data on pathogens, antimicrobial resistance, and outcomes remain limited. We described epidemiology, antimicrobial susceptibility, multidrug-resistant (MDR) phenotype prevalence, and unadjusted associations between MDR phenotypes and 30-day in-hospital mortality among maintenance hemodialysis BSI episodes.
methodsThis single-center retrospective cohort included maintenance hemodialysis patients with positive blood cultures at Aseer Central Hospital, southern Saudi Arabia, from January 2013 through July 2024. Analyses were structured by unit of analysis: unique patients, BSI episodes (after 14-day deduplication), isolates, and hospitalized episodes for mortality. Susceptibility used CLSI M100 categorical results. Unadjusted risk ratios with 95% confidence intervals and Fisher exact tests were descriptive; no multivariable model was fitted (sparse events).
results201 patients contributed 297 BSI episodes and 389 isolates; 234 hospitalized. Gram-positive organisms predominated (69.0%), led by staphylococci other than Staphylococcus aureus (SOSA, 42.8%), Enterobacterales (21.2%), and S. aureus (17.2%). The 30-day in-hospital mortality was 11.1% (26/234). Linezolid (99.2%) and vancomycin (96.0%) were most active; fluoroquinolone susceptibility was low (45-49%). MDR phenotypes occurred in 24.2% of isolates (MRSA 56.4%, ESC-R 65.0%, CRE 27.3%, VRE 29.2%, CRAB 80.0%). Organism-restricted analysis found CRE-positive episodes with higher mortality than carbapenem-susceptible Enterobacterales (3/8 vs. 1/21), without conventional significance (risk ratio 7.88, 95% CI 0.95-65.06; P = 0.053).
conclusionsBSI were predominantly gram-positive with a substantial gram-negative and MDR burden. The CRE-mortality association was unadjusted, imprecise, and hypothesis-generating, requiring confirmation in larger adjusted cohorts. Findings support local antimicrobial stewardship and active MDR surveillance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.